English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17482/19768 (88%)
Visitors : 6336030      Online Users : 296
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32601


    標題: Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models
    作者: Cheng, Kai-Chun
    Li, Yingxiao
    Chang, Wei-Ting
    Zhih-Cherng Chen(陳志成)
    Cheng, Juei-Tang
    Tsai, Cheng-Chia
    貢獻者: Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychosomat Internal Med
    Chi Mei Med Ctr, Dept Med Res
    Chi Mei Med Ctr, Dept Cardiol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chang Jung Christian Univ, Grad Inst Med Sci
    Mackay Med Univ, Mackay Mem Hosp, Dept Surg
    關鍵字: Hypertrophic signals
    Hyperglycemia
    H9c2 cells
    Isoproterenol
    Potassium bromate
    日期: 2019-01
    上傳時間: 2020-07-29 13:51:36 (UTC+8)
    出版者: FOOD & DRUG ADMINSTRATION
    摘要: Cardiac hypertrophy is widely diagnosed in clinical cardiac disorders. The pathophysiology of hypertrophy is complex and multifactorial, a series of molecular and cellular changes are participated, such as activation of different signaling pathways, a switch of fetal gene program in the myocardium, and apoptosis. Some biomarkers have been applied to assess cardiac hypertrophy including atrial natriuretic peptides (ANP), brain/B-type natriuretic peptides (BNP), and alpha- or beta- Myosin Heavy Chain (MHC) in addition to others. Recently, ubiquitin-protein ligase E3A (UBE3A) has been observed to increase in cardiac hypertrophy. Therefore, UBE3A as a new biomarker seems valuable in the clinic. The cardiac hypertrophy is induced in rat-derived heart cell line H9c2 cells by potassium bromate (KBrO3), high glucose (HG), or isoproterenol (Iso), respectively. As an oxidizing agent, KBrO3 increased cell size at concentrations less than 250 mu M. Similarly, HG and Iso also induced cardiac hypertrophy in H9c2 cells. Interestingly, each kind of the cell models promoted the gene expression of the well-known biomarkers of cardiac hypertrophy including atrial natriuretic peptides (ANP) and brain/B- type natriuretic peptides (BNP). Additionally, UBE3A is also raised with the signals involved in cardiac hypertrophy such as calcineurin and nuclear factor of activated T-cells (NFAT) determined using Western blots. KBrO3 increased the protein levels of these signals and the specific inhibitor, such as cyclosporine A and tacrolimus, attenuated the signaling in H9c2 cells at concentrations sufficient to inhibit calcineurin in addition to the reduction of mRNA levels of UBE3A, similar to ANP or BNP. Moreover, HG or Iso also significantly increased protein levels of UBE3A in H9c2 cells. Taken together, we provided a new view that UBE3A is markedly raised in cardiac hypertrophy using various cell models, mainly through the activation of the calcineurin/NFAT signaling pathway in H9c2 cells. Therefore, UBE3A could be developed as a new biomarker in the diagnosis of cardiac hypertrophy. Copyright (C) 2018, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC.
    關聯: Journal of Food and Drug Analysis, v.27, n.1, pp. 355-364
    Appears in Collections:[藥學系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1016-j.jfda.2018.08.002.pdf1105KbAdobe PDF18View/Open
    index.html0KbHTML52View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback